IN VIVO TESTING NIH GUIDE, Volume 21, Number 28, August 7, 1992 RFP AVAILABLE: NCI-CM-37821-12 P.T. 34 Keywords: Screening of Drugs/Agents Cell Lines National Cancer Institute Request for Proposals (RFP) Nos. NCI-CM-37821-12 (formerly NCI-CM-37821-28) and NCI-CM-37830-12 will be issued upon written request to Joyce Crooke, Contract Specialist, on or about August 7, 1992. Proposals will be due on or about September 28, 1992. A major objective of the Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), is the testing for and evaluation of activity of compounds in in vitro cell lines and in vivo tumor systems. DTP is soliciting organizations having the necessary experience, scientific and technical personnel, and facilities to conduct in vivo testing of compounds that have demonstrated in vitro activity against a battery of human tumor cell lines. Secondary in vivo testing is essential in order to confirm activity of a compound and further define its specificity. The studies to be performed may require any or all of the following: direct on-site support at the Contractor's facility for in vitro expansion of cell lines and initial in vivo assays utilizing rapid and sensitive procedures; detailed follow-up in vivo studies; investigation into the effect of formulation, treatment schedules, route of drug administration, and site of tumor implantation on drug activity. The Contractor will be required to receive, maintain, and experimentally use regular and/or athymic nude mice; propagate and maintain tumor stock in vivo; prepare and administer test materials to tumor-bearing and nontumor-bearing animals; monitor the quality of all tumor lines and mice; determine test material activity; and report the results. The Government will designate and supply the agents to be tested. The Contractor will be expected to provide all equipment and animal facilities needed to conduct this type of work. The following Mandatory Qualification Criteria will apply: (1) the Contractor may not be a pharmaceutical or chemical firm since compounds of a commercially confidential nature (discreet) may be evaluated; (2) since structural formulae and other information on discreet compounds may be included, Contractors must be willing to sign a confidentiality of information statement. RFP No. NCI-CM-37821-12, In Vivo Testing, is an open competition. RFP No. NCI-CM-37830-12, In Vivo Testing, is a 100 percent Set-Aside for Small Business. The Standard Industrial Code (SIC) is 8731. Offerors who qualify as a small business are encouraged to submit proposals under both RFPs. It is anticipated that a total of two incrementally-funded, cost-reimbursement completion contracts will be awarded between these RFPs with the contract period beginning on or about June 1, 1993. The contract period will be five years. INQUIRIES RFP requests are to be addressed to: Joyce Crooke Contract Specialist National Cancer Institute Executive Plaza South, Room 603 9000 Rockville Pike Bethesda, MD 20892 Telephone: (301) 496-8628 No collect calls will be accepted. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |